From Promise to Practice A HEALinc Global Summit White Paper
DOI:
https://doi.org/10.13052/ijts2246-8765.2026.001Keywords:
Regenerative medicine, longevity science, translational medicine, global standard of care, responsible global access, healthspan, risk-adapted regulation, governed learning environments, real-world evidence, evidence portability, whole-person health, patient agency, health equity, HEALinc Global Translation ArchitectureAbstract
This paper, developed by HEALinc CEO and Founder Dr. Desirée Cox, translates a day of multidisciplinary discussion at the 2026 HEALinc Global Summit, New York City (NYC) Day Conclave into a coherent systems framework and action agenda. It is not a transcript, clinical guideline, regulatory opinion, or endorsement of every intervention or claim discussed at the Summit.
The source material captures perspectives from scientists, physicians, biotechnology leaders, lawyers, investors, former regulators, patient advocates, educators, architects, and other participants. Sponsors, speakers, and key opinion leaders represented at the HEALinc New York City (NYC) Day Conclave are identified in the Appendices. The proceedings ranged from late-stage clinical development and international regulatory pathways to whole-person health, patient experience, digital monitoring, medical education, and the design of healing environments. The purpose of this paper is to identify the recurring system-level insights, clarify where genuine convergence occurred, and convert those insights into a practical architecture for translation.
Some interventions and outcomes described during the discussions were preliminary, anecdotal, contested, or outside established standards of evidence. They are treated here as signals of emerging questions and unmet needs – not as validated clinical conclusions. Any therapy must be evaluated according to its own evidence, manufacturing quality, ethical acceptability, regulatory status, and risk profile.
Interpretive Stance
The field should neither equate regulatory caution with obstruction nor equate permissive access with progress. The task is to create controlled velocity: faster, more coherent learning and access under stronger evidence, ethics, quality, and accountability.
Downloads
References
A. Translational science, implementation and learning health systems
S. H. Woolf, “The meaning of translational research and why it matters,” JAMA, vol. 299, no. 2, pp. 211–213, 2008, doi: 10.1001/jama.2007.26.
Institute of Medicine, Best Care at Lower Cost: The Path to Continuously Learning Health Care in America. Washington, DC, USA: National Academies Press, 2013, doi: 10.17226/13444.
C. P. Friedman, J. C. Rubin, J. S. Brown, M. B. Buntin, M. Corn, L. M. Etheredge, et al., “Toward a science of learning systems: A research agenda for the high-functioning learning health system,” J. Am. Med. Inform. Assoc., vol. 22, no. 1, pp. 43–50, 2015, doi: 10.1136/amiajnl-2014-002977.
L. J. Damschroder, D. C. Aron, R. E. Keith, S. R. Kirsh, J. A. Alexander, and J. C. Lowery, “Fostering implementation of health services research findings into practice: A consolidated framework for advancing implementation science,” Implement. Sci., vol. 4, p. 50, 2009, doi: 10.1186/1748-5908-4-50.
National Academies of Sciences, Engineering, and Medicine, Crossing the Global Quality Chasm: Improving Health Care Worldwide. Washington, DC, USA: National Academies Press, 2018, doi: 10.17226/25152.
M. E. Kruk, A. D. Gage, C. Arsenault, et al., “High-quality health systems in the Sustainable Development Goals era: Time for a revolution,” Lancet Glob. Health, vol. 6, no. 11, pp. e1196–e1252, 2018, doi: 10.1016/S2214-109X(18)30386-3.
These sources support the paper’s argument that translation is an institutional and systems achievement rather than a linear movement from laboratory discovery to market authorization.
B. Regenerative medicine, longevity, healthspan, and intrinsic capacity
A. S. Mao and D. J. Mooney, “Regenerative medicine: Current therapies and future directions,” Proc. Natl. Acad. Sci. USA, vol. 112, no. 47, pp. 14452–14459, 2015, doi: 10.1073/pnas.1508520112.
World Health Organization, World Report on Ageing and Health. Geneva, Switzerland: World Health Organization, 2015, ISBN 978-92-4-156504-2.
J. R. Beard, A. Officer, I. A. de Carvalho, R. Sadana, A. M. Pot, J. P. Michel, P. Lloyd-Sherlock, J. Epping-Jordan, G. C. E. Peeters, W. R. Mahanani, J. Thiyagarajan, and S. Chatterji, “The World report on ageing and health: A policy framework for healthy ageing,” Lancet, vol. 387, no. 10033, pp. 2145–2154, 2016, doi: 10.1016/S0140-6736(15)00516-4.
World Health Organization, Integrated Care for Older People: Guidelines on Community-Level Interventions to Manage Declines in Intrinsic Capacity. Geneva, Switzerland: World Health Organization, 2017.
World Health Organization, Integrated Care for Older People Implementation Framework: Guidance for Systems and Services. Geneva, Switzerland: World Health Organization, 2019.
World Health Organization, Integrated Care for Older People: Guidance for Person-Centred Assessment and Pathways in Primary Care, 2nd ed. Geneva, Switzerland: World Health Organization, 2025, ISBN 978-92-4-010372-6.
M. Cesari, I. A. Carvalho, J. A. Thiyagarajan, J. M. Cooper, B. Martin, E. E. Araujo de Carvalho, A. Amuthavalli Thiyagarajan, A. Beard, and S. Chatterji, “Evidence for the domains supporting the construct of intrinsic capacity,” J. Gerontol. A Biol. Sci. Med. Sci., vol. 73, no. 12, pp. 1653–1660, 2018, doi: 10.1093/gerona/gly011.
C. López-Otín, M. A. Blasco, L. Partridge, M. Serrano, and G. Kroemer, “The hallmarks of aging,” Cell, vol. 153, no. 6, pp. 1194–1217, 2013, doi: 10.1016/j.cell.2013.05.039.
C. López-Otín, M. A. Blasco, L. Partridge, M. Serrano, and G. Kroemer, “Hallmarks of aging: An expanding universe,” Cell, vol. 186, no. 2, pp. 243–278, 2023, doi: 10.1016/j.cell.2022.11.001.
B. K. Kennedy, S. L. Berger, A. Brunet, J. Campisi, A. M. Cuervo, E. S. Epel, C. Franceschi, G. Lithgow, A. N. Madeo, M. Passarino, K. B. Rando, E. Verdin, P. S. West, and A. J. B. M. Wyss-Coray, “Geroscience: Linking aging to chronic disease,” Cell, vol. 159, no. 4, pp. 709–713, 2014, doi: 10.1016/j.cell.2014.10.039.
L. Ferrucci, M. Gonzalez-Freire, E. Fabbri, B. Simonsick, A. Tanaka, B. Moore, M. Salimi, A. Sierra, A. K. M. M. Barzilai, and J. B. A. C. De Cabo, “Measuring biological aging in humans: A quest,” Aging Cell, vol. 19, no. 2, p. e13080, 2020, doi: 10.1111/acel.13080.
J. N. Justice, L. Ferrucci, A. B. Newman, E. A. A. A. Reuben, S. B. Walston, R. J. Harris, A. B. B. A. Seals, and M. E. K. A. Kuchel, “A framework for selection of blood-based biomarkers for geroscience-guided clinical trials: Report from the TAME Biomarkers Workgroup,” Geroscience, vol. 40, nos. 5–6, pp. 419–436, 2018, doi: 10.1007/s11357-018-0042-y.
E. M. Crimmins, “Lifespan and healthspan: Past, present, and promise,” Gerontologist, vol. 55, no. 6, pp. 901–911, 2015, doi: 10.1093/geront/gnv130.
These references are particularly relevant to Sections 2, 4, and 6 and to the paper’s proposed glossary, outcome framework, and emphasis on function rather than lifespan alone.
C. Research ethics, regulatory architecture, staged access, and regulatory reliance
World Medical Association, WMA Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Participants. Ferney-Voltaire, France: World Medical Association, 2024.
Council for International Organizations of Medical Sciences, International Ethical Guidelines for Health-Related Research Involving Humans, 4th ed. Geneva, Switzerland: CIOMS, 2016, doi: 10.56759/rgxl7405.
World Health Organization, Guidance for Best Practices for Clinical Trials. Geneva, Switzerland: World Health Organization, 2024, ISBN 978-92-4-009771-1.
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, ICH E6(R3): Guideline for Good Clinical Practice, final consolidated version, adopted Jun. 16, 2026, 2026.
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, ICH E8(R1): General Considerations for Clinical Studies, 2021.
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, ICH E9(R1): Addendum on Estimands and Sensitivity Analysis in Clinical Trials, 2019.
References [20–25] provide the principal ethical and methodological guardrails for the paper’s concept of “controlled velocity.”
World Health Organization, Good Regulatory Practices in the Regulation of Medical Products, WHO Technical Report Series, no. 1033, Annex 11. Geneva, Switzerland: World Health Organization, 2021.
World Health Organization, Good Reliance Practices in the Regulation of Medical Products: High-Level Principles and Considerations, WHO Technical Report Series, no. 1033, Annex 10. Geneva, Switzerland: World Health Organization, 2021.
WHO defines regulatory reliance as using or giving substantial weight to work performed by another trusted authority while retaining local responsibility for the decision. This is directly aligned with the White Paper’s distinction between interoperability and regulatory uniformity.
H. G. Eichler, K. Oye, L. G. Baird, R. Abadie, J. Brown, C. Drumond, E. Ferguson, S. Garner, L. M. Honig, M. J. K. Lemery, S. M. Leufkens, and S. M. Ford, “Adaptive licensing: Taking the next step in the evolution of drug approval,” Clin. Pharmacol. Ther., vol. 91, no. 3, pp. 426–437, 2012, doi: 10.1038/clpt.2011.345.
U.S. Food and Drug Administration, Expedited Programs for Regenerative Medicine Therapies for Serious Conditions: Guidance for Industry. Silver Spring, MD, USA: U.S. Food and Drug Administration, 2019.
U.S. Food and Drug Administration, Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use: Guidance for Industry and Food and Drug Administration Staff. Silver Spring, MD, USA: U.S. Food and Drug Administration, 2017.
U.S. Food and Drug Administration, Long Term Follow-Up After Administration of Human Gene Therapy Products: Guidance for Industry. Silver Spring, MD, USA: U.S. Food and Drug Administration, 2020.
U.S. Food and Drug Administration, FDA Acceptance of Foreign Clinical Studies Not Conducted Under an IND: Frequently Asked Questions: Guidance for Industry. Silver Spring, MD, USA: U.S. Food and Drug Administration, 2012.
U.S. Food and Drug Administration, Adaptive Designs for Clinical Trials of Drugs and Biologics: Guidance for Industry. Silver Spring, MD, USA: U.S. Food and Drug Administration, 2019.
Ministry of Health, Labour and Welfare, Japan, Guidance for Conditional and Time-Limited Approval for Regenerative Medical Products and the Development of Subsequent Efficacy Evaluation Plan, PSB/MDED Notification No. 0329-3, 2024.
Ministry of Health, Labour and Welfare, Japan, Handling of the Conditional and Time-Limited Approval for Regenerative Medical Products, PSB/MDED Notification No. 1006-1, 2025.
The Japanese documents are especially relevant to the staged regulatory model, post-authorization evidence requirements, mandatory surveillance, and the possibility of withdrawal when efficacy is not confirmed.
European Parliament and Council of the European Union, “Regulation (EC) No. 1394/2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No. 726/2004,” Official Journal of the European Union, vol. L 324, pp. 121–137, 2007.
Commonwealth of The Bahamas, Longevity and Regenerative Therapies Act, 2024, no. 51 of 2024, 2024.
Commonwealth of The Bahamas, Longevity and Regenerative Therapies Act, 2024 (Appointed Day) Notice, 2024, S.I. no. 73 of 2024, 2024.
The Bahamian Act received assent on 26 July 2024 and came into force on 1 September 2024.
D. Evidence architecture, outcomes, real-world evidence, manufacturing, and data portability
J. Woodcock and L. M. LaVange, “Master protocols to study multiple therapies, multiple diseases, or both,” N. Engl. J. Med., vol. 377, no. 1, pp. 62–70, 2017, doi: 10.1056/NEJMra1510062.
R. E. Sherman, S. A. Anderson, G. J. Dal Pan, G. W. Gray, T. Gross, N. L. Hunter, L. LaVange, D. Marinac-Dabic, P. W. Miller, L. K. Robb, J. Shuren, and R. Temple, “Real-world evidence – What is it and what can it tell us?” N. Engl. J. Med., vol. 375, no. 23, pp. 2293-2297, 2016, doi: 10.1056/NEJMsb1609216.
M. Calvert, J. Blazeby, D. G. Altman, D. Revicki, D. Moher, and R. A. Brundage, “Reporting of patient-reported outcomes in randomized trials: The CONSORT PRO extension,” JAMA, vol. 309, no. 8, pp. 814–822, 2013, doi: 10.1001/jama.2013.879.
M. Calvert, D. Kyte, R. Mercieca-Bebber, C. A. Slade, P. Chan, P. King, M. J. H. Clinch, S. E. Arpin, J. A. O’Connor, D. Revicki, D. Moher, J. P. A. Brundage, and SPIRIT-PRO Group, “Guidelines for inclusion of patient-reported outcomes in clinical trial protocols: The SPIRIT-PRO extension,” JAMA, vol. 319, no. 5, pp. 483–494, 2018, doi: 10.1001/jama.2017.21903.
P. R. Williamson, D. G. Altman, H. Bagley, G. Barnes, J. Blazeby, K. Brookes, P. Clarke, J. Gargon, and D. Gorst, “The COMET Handbook: Version 1.0,” Trials, vol. 18, suppl. 3, p. 280, 2017, doi: 10.1186/s13063-017-1978-4.
M. D. Wilkinson, M. Dumontier, I. J. J. Aalbersberg, et al., “The FAIR Guiding Principles for scientific data management and stewardship,” Sci. Data, vol. 3, p. 160018, 2016, doi: 10.1038/sdata.2016.18.
U.S. Food and Drug Administration, Considerations for the Use of Real-World Data and Real-World Evidence to Support Regulatory Decision-Making for Drug and Biological Products: Guidance for Industry. Silver Spring, MD, USA: U.S. Food and Drug Administration, 2023.
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, ICH Q5E: Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process, 2004.
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, ICH Q6B: Specifications – Test Procedures and Acceptance Criteria for Biotechnological/Biological Products, 1999.
U.S. Food and Drug Administration, Potency Tests for Cellular and Gene Therapy Products: Guidance for Industry. Silver Spring, MD, USA: U.S. Food and Drug Administration, 2011.
International Society for Stem Cell Research, Guidelines for Stem Cell Research and Clinical Translation, ver. 1.2. International Society for Stem Cell Research, 2025.
The current ISSCR guidelines emphasize scientific rigor, independent oversight, transparency, responsible communication, and evidence-based clinical translation.
J. A. Welsh, D. C. I. Goberdhan, L. O’Driscoll, et al., “Minimal information for studies of extracellular vesicles – MISEV2023: From basic to advanced approaches,” J. Extracell. Vesicles, vol. 13, no. 2, p. e12404, 2024, doi: 10.1002/jev2.12404.
Z. Master, K. R. W. Matthews, and M. Abou-El-Enein, “Unproven stem cell interventions: A global public health problem requiring global deliberation,” Stem Cell Reports, vol. 16, no. 6, pp. 1435–1445, 2021, doi: 10.1016/j.stemcr.2021.05.004.
These sources collectively support the paper’s seven-level outcome framework, use of patient-reported outcomes, core outcome sets, master protocols, real-world evidence, data interoperability, and the proposition that manufacturing is part of the clinical claim.
E. Global access, medical travel, affordability and reimbursement
R. Johnston, V. A. Crooks, J. Snyder, and P. Kingsbury, “What is known about the effects of medical tourism in destination and departure countries? A scoping review,” Int. J. Equity Health, vol. 9, p. 24, 2010, doi: 10.1186/1475-9276-9-24.
V. A. Crooks, P. Kingsbury, J. Snyder, and R. Johnston, “What is known about the patient’s experience of medical tourism? A scoping review,” BMC Health Serv. Res., vol. 10, p. 266, 2010, doi: 10.1186/1472-6963-10-266.
L. P. Garrison, Jr., A. Towse, A. Briggs, et al., “Performance-based risk-sharing arrangements-Good practices for design, implementation, and evaluation,” Value Health, vol. 16, no. 5, pp. 703–719, 2013, doi: 10.1016/j.jval.2013.04.011.
J. Jørgensen and P. Kefalas, “The use of innovative payment mechanisms for gene therapies in Europe and the USA,” Regen. Med., vol. 16, no. 4, pp. 405–422, 2021, doi: 10.2217/rme-2020-0169.
National Academies of Sciences, Engineering, and Medicine, Making Medicines Affordable: A National Imperative. Washington, DC, USA: National Academies Press, 2018, doi: 10.17226/24946.
These references are especially relevant to the distinction between temporary cross-border access and a durable global-access system, as well as outcomes-based payment, risk-sharing, affordability and continuity of care.
F. Whole-person health, patient agency, trust, and healing environments
G. L. Engel, “The need for a new medical model: A challenge for biomedicine,” Science, vol. 196, no. 4286, pp. 129–136, 1977, doi: 10.1126/science.847460.
World Health Assembly, Framework on Integrated, People-Centred Health Services, document A69/39 and resolution WHA69.24. Geneva, Switzerland: World Health Organization, 2016.
World Health Organization, WHO Guidelines on Physical Activity and Sedentary Behaviour. Geneva, Switzerland: World Health Organization, 2020, ISBN 978-92-4-001512-8.
World Health Organization, WHO Housing and Health Guidelines. Geneva, Switzerland: World Health Organization, 2018, ISBN 978-92-4-155037-6.
R. S. Ulrich, “View through a window may influence recovery from surgery,” Science, vol. 224, no. 4647, pp. 420–421, 1984, doi: 10.1126/science.6143402.
H. Frumkin, G. N. Bratman, S. J. Breslow, et al., “Nature contact and human health: A research agenda,” Environ. Health Perspect., vol. 125, no. 7, p. 075001, 2017, doi: 10.1289/EHP1663.
G. Elwyn, D. Frosch, R. Thomson, et al., “Shared decision making: A model for clinical practice,” J. Gen. Intern. Med., vol. 27, no. 10, pp. 1361–1367, 2012, doi: 10.1007/s11606-012-2077-6.
K. L. Carman, P. Dardess, M. Maurer, et al., “Patient and family engagement: A framework for understanding the elements and developing interventions and policies,” Health Aff., vol. 32, no. 2, pp. 223–231, 2013, doi: 10.1377/hlthaff.2012.1133.
National Academies of Sciences, Engineering, and Medicine, Communicating Science Effectively: A Research Agenda. Washington, DC, USA: National Academies Press, 2017, doi: 10.17226/23674.
These sources support the paper’s five-layer whole-person care model, its focus on function and participation, its patient trust compact, and its recognition that environmental design and public communication affect health and adoption.
G. Artificial intelligence, continuous data and digital governance
World Health Organization, Ethics and Governance of Artificial Intelligence for Health: WHO Guidance. Geneva, Switzerland: World Health Organization, 2021, ISBN 978-92-4-002920-0.
World Health Organization, Regulatory Considerations on Artificial Intelligence for Health. Geneva, Switzerland: World Health Organization, 2023, ISBN 978-92-4-007887-1.
U.S. Food and Drug Administration and European Medicines Agency, Guiding Principles of Good AI Practice in Drug Development, 2026.
The joint FDA-EMA principles emphasize human-centered design, risk-based use, data governance, context of use, performance assessment, and lifecycle management.
X. Liu, S. Cruz Rivera, D. Moher, M. J. Calvert, and A. K. Denniston, “Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: The CONSORT-AI extension,” Nat. Med., vol. 26, pp. 1364–1374, 2020, doi: 10.1038/s41591-020-1034-x.
S. Cruz Rivera, X. Liu, A. W. Chan, A. K. Denniston, and M. J. Calvert, “Guidelines for clinical trial protocols for interventions involving artificial intelligence: The SPIRIT-AI extension,” Nat. Med., vol. 26, pp. 1351–1363, 2020, doi: 10.1038/s41591-020-1037-7.
Z. Obermeyer, B. Powers, C. Vogeli, and S. Mullainathan, “Dissecting racial bias in an algorithm used to manage the health of populations,” Science, vol. 366, no. 6464, pp. 447–453, 2019, doi: 10.1126/science.aax2342.
H. Internal HEALinc source documents
These should be cited in the methodology or source-base appendix as unpublished proceedings, not as independent scientific validation of therapeutic claims.
HEALinc Global Summit, Keynote Q&A Sessions and Discussion Summaries, Day 2, New York City, May 13, 2026, unpublished draft proceedings, 2026.
HEALinc Global Summit, HEALinc NYC Audio 1 Transcript, Day 2, May 13, 2026, unpublished transcript, 2026.
HEALinc Global Summit, HEALinc NYC Audio 2 Transcript, Day 2, May 13, 2026, unpublished transcript, 2026.
HEALinc Global Summit, HEALinc NYC Audio 3 Transcript, Day 2, May 13, 2026, unpublished transcript, 2026.
I. FDA draft references
These may be valuable where the White Paper discusses the direction of current regulatory reform, but they must be labeled draft guidance – not for implementation:
U.S. Food and Drug Administration. 2025. Expedited Programs for Regenerative Medicine Therapies for Serious Conditions: Draft Guidance for Industry.
U.S. Food and Drug Administration. 2025. Postapproval Methods to Capture Safety and Efficacy Data for Cell and Gene Therapy Products: Draft Guidance for Industry.
U.S. Food and Drug Administration. 2025. Innovative Designs for Clinical Trials of Cellular and Gene Therapy Products in Small Populations: Draft Guidance for Industry.
